FDA Grants Orphan Drug Designation For Lennox-Gastaut Syndrome Treatment

Lennox-Gastaut syndrome (LGS) is a severe and rare form of epilepsy, which causes patients to often have multiple seizures a day. It generally appears in early childhood, and is difficult to treat. In severe cases, it may be fatal. To learn more about LGS, click here.

Ovid Therapeutics Inc., a company that focuses on creating medicines for people with rare diseases, saw the need for a better LGS treatment. They have been working with Takeda Pharmaceutical Company Limited on the treatment TAK-935/OV935.

On January 20th, the company announced that TAK-935/OV935 had received Orphan Drug Designation from the FDA to speed up the process.
Learn more about it on Public here.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email